Loading…
Reported covered position: Legislative Director, Senator Bob Graham ; ; Staff Director, Senate Committee on Veterans Affairs
How to read the money
Income and expense are whole-filing amounts associated with this lobbyist, not personal compensation or an allocated share.
No topic inference: each bill number appears in source LDA issue text assigned to this lobbyist.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, LLC · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to multi-cancer early detection screening; H.R. 2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act (118th Congress).
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Specific issues are shown only where the LDA source assigned them to this lobbyist. Targets apply to the associated filing.
TIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS) via TIBER CREEK HEALTH STRATEGIES, INC.
2025 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (OBO JAZZ PHARMACEUTICALS) via TIBER CREEK HEALTH STRATEGIES, INC.
2025 · first_quarter · Q1
Source: Senate LDA
| TIBER CREEK GROUP (OBO JAZZ PHARMACEUTICALS) |
| 27 |
| 2019–2025 |
| TIBER CREEK GROUP (ON BEHALF OF EMD SERONO, INC.) | 27 | 2016–2024 |
| ELI LILLY AND COMPANY | 22 | 2020–2025 |
| TIBER CREEK GROUP (ON BEHALF OF BRISTOL MYERS SQUIBB) | 21 | 2020–2024 |
| FRESENIUS MEDICAL CARE NORTH AMERICA | 18 | 2020–2025 |
| PECK MADIGAN JONES (ON BEHALF OF CAPG) | 18 | 2014–2018 |
| PECK MADIGAN JONES (ON BEHALF OF INNOVACARE, INC.) | 17 | 2014–2019 |
| PECK MADIGAN JONES (ON BEHALF OF BIO) | 16 | 2011–2014 |
| PECK MADIGAN JONES (ON BEHALF OF FWD.US) | 12 | 2013–2017 |
| PECK MADIGAN JONES (ON BEHALF OF MICRON TECHNOLOGY, INC.) | 11 | 2013–2015 |
| PECK MADIGAN JONES (ON BEHALF OF ROIVANT SCIENCES, INC.) | 11 | 2018–2020 |
| PECK MADIGAN JONES (ON BEHALF OF ABBVIE INC.) | 10 | 2013–2015 |
| PECK MADIGAN JONES (ON BEHALF OF CELGENE CORPORATION) | 9 | 2018–2019 |
| COMPREHENSIVE HEALTH MANAGEMENT, INC. | 8 | 2018–2019 |
| DAIICHI SANKYO INC | 7 | 2011–2012 |
| PECK MADIGAN JONES (ON BEHALF OF BIOSCRIP) | 7 | 2017–2019 |
| GRAIL, LLC | 6 | 2024–2025 |
| PECK MADIGAN JONES (ON BEHALF OF ASSOCIATION FOR CLINICAL ONCOLOGY) | 5 | 2020 |
| PECK MADIGAN JONES (ON BEHALF OF PREVENT OPIOID ABUSE) | 5 | 2020 |
| PECK MADIGAN JONES (ON BEHALF OF AMERICAN SOCIETY OF CLINICAL ONCOLOGY) | 4 | 2019 |
| PECK, MADIGAN, JONES & STEWART (ON BEHALF OF SEMICONDUCTOR INDUSTRY ASSOCIATION) | 4 | 2011–2012 |
| BAY BRIDGE STRATEGIES, INC. (ON BEHALF OF BIOCRYST PHARMACEUTICALS) | 3 | 2013 |
| PECK MADIGAN JONES (ON BEHALF OF LEGACY COMMUNITY HEALTH SERVICES) | 3 | 2014–2020 |
| ICKES AND ENRIGHT GROUP (ON BEHALF OF NORTHWEST BIOTHERAPEUTICS) | 2 | 2016 |
| PECK MADIGAN JONES (ON BEHALF OF ACADIA PHARMACEUTICALS, INC.) | 1 | 2020 |
| PECK MADIGAN JONES (ON BEHALF OF BEIGENE USA, INC.) | 1 | 2020 |
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act (118th Congress).
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act (118th Congress).
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, LLC · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to multi-cancer early detection screening; H.R. 2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, LLC · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to multi-cancer early detection screening; H.R. 2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, LLC · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to multi-cancer early detection screening; H.R. 2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act
Client: GRAIL, LLC · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to multi-cancer early detection screening; H.R. 2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R.5547/S. 476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R.5547/S. 476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R.5547/S. 476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R.5547/S. 476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R.5547/S. 476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R.5547/S. 476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R.5547/S. 476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R.5547/S. 476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); S. 476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); S. 476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); S. 476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); S. 476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); S. 476 - Maintaining Investments in New Innovation Act.
Maintaining Investments in New Innovation Act
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); S. 476 - Maintaining Investments in New Innovation Act.
Inflation Reduction Act of 2022
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 as renamed - Inflation Reduction Act - Subtitle B; Parts B and D drug pricing.
Inflation Reduction Act of 2022
Client: AMGEN, INC. · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
Inflation Reduction Act of 2022
Client: TIBER CREEK GROUP (ON BEHALF OF EMD SERONO, INC.) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
Inflation Reduction Act of 2022
Client: AMGEN, INC. · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 - as renamed - Inflation Reduction Act - Subtitle B Parts B and D Medicare Drug Pricing.
Inflation Reduction Act of 2022
Client: TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 as renamed - Inflation Reduction Act - Subtitle B, Parts B and D drug pricing.
Inflation Reduction Act of 2022
Client: TIBER CREEK GROUP (OBO JAZZ PHARMACEUTICALS) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 - Build Back Better Act, issues related to drug pricing.
Inflation Reduction Act of 2022
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
Inflation Reduction Act of 2022
Client: ELI LILLY AND COMPANY · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 as renamed - Inflation Reduction Act - Subtitle B; Parts B and D Medicare Drug Pricing.
Inflation Reduction Act of 2022
Client: TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
Inflation Reduction Act of 2022
Client: TIBER CREEK GROUP (ON BEHALF OF BRISTOL MYERS SQUIBB) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 as renamed - Inflation Reduction Act - Subtitle B, Parts B and D drug pricing.
Inflation Reduction Act of 2022
Client: TIBER CREEK GROUP (ON BEHALF OF BRISTOL MYERS SQUIBB) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
Inflation Reduction Act of 2022
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
Inflation Reduction Act of 2022
Client: AMGEN, INC. · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
Inflation Reduction Act of 2022
Client: GENENTECH, INC. · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 - Build Back Better Act, Part B drug pricing.
Inflation Reduction Act of 2022
Client: ELI LILLY AND COMPANY · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
Inflation Reduction Act of 2022
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
Inflation Reduction Act of 2022
Client: TIBER CREEK GROUP (OBO JAZZ PHARMACEUTICALS) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 - Build Back Better Act, issues related to drug pricing.
Inflation Reduction Act of 2022
Client: TIBER CREEK GROUP (ON BEHALF OF BRISTOL MYERS SQUIBB) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
Inflation Reduction Act of 2022
Client: GENENTECH, INC. · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 as renamed - Inflation Reduction Act - Subtitle B; Part B drug pricing.
Inflation Reduction Act of 2022
Client: TIBER CREEK GROUP (OBO JAZZ PHARMACEUTICALS) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 as renamed - Inflation Reduction Act - Subtitle B; Part D drug pricing.
Inflation Reduction Act of 2022
Client: TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
Inflation Reduction Act of 2022
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
Affordable Insulin Now Act
Client: ELI LILLY AND COMPANY · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to insulin pricing, S. 3700 - Affordable Insulin Now Act.
Affordable Insulin Now Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to S. 3700 - Affordable Insulin Now Act, insulin pricing.
Affordable Insulin Now Act
Client: ELI LILLY AND COMPANY · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to insulin pricing, S. 3700 - Affordable Insulin Now Act.
Affordable Insulin Now Act
Client: ELI LILLY AND COMPANY · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to insulin pricing, S. 3700 - Affordable Insulin Now Act.
Restore Protections for Dialysis Patients Act
Client: FRESENIUS MEDICAL CARE NORTH AMERICA · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
S. 4750 Restore Protections for Dialysis Patients Act.
David’s Law
Client: TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 133/PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act.
David’s Law
Client: TIBER CREEK GROUP (ON BEHALF OF EMD SERONO, INC.) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 133/PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act.
David’s Law
Client: TIBER CREEK GROUP (ON BEHALF OF BRISTOL MYERS SQUIBB) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to drug pricing; H.R. 133/PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act.
H.R. 133/PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act.
David’s Law
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 133/PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act.
H.R. 133/PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act.
David’s Law
Client: TIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues relating to drug pricing; H.R. 133/PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act.
Inflation Reduction Act of 2022
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
Inflation Reduction Act of 2022
Client: TIBER CREEK GROUP (ON BEHALF OF BRISTOL MYERS SQUIBB) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
Inflation Reduction Act of 2022
Client: TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
Inflation Reduction Act of 2022
Client: AMGEN, INC. · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
Inflation Reduction Act of 2022
Client: ELI LILLY AND COMPANY · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
Inflation Reduction Act of 2022
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 5376 - Build Back Better Act, Subtitle J (Part B and D drug pricing).
Blackfoot Clearwater Stewardship Act
Client: AMGEN, INC. · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to Part B and D drug pricing reform; S.1493 - Increasing Access to Osteoporosis Testing for Medicare Beneficiaries Act of 2021.
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to Part B and Part D pricing; S. 3353 - Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020.
Consolidated Appropriations Act, 2021
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act
Consolidated Appropriations Act, 2021
Client: TIBER CREEK GROUP (ON BEHALF OF BRISTOL MYERS SQUIBB) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to drug pricing. H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act
Consolidated Appropriations Act, 2021
Client: TIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues relating to drug pricing; H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act
Consolidated Appropriations Act, 2021
Client: AMGEN, INC. · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Part B home infusion issues; H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act
Consolidated Appropriations Act, 2021
Client: ELI LILLY AND COMPANY · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act
Consolidated Appropriations Act, 2021
Client: TIBER CREEK GROUP (ON BEHALF OF EMD SERONO, INC.) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act
Consolidated Appropriations Act, 2021
Client: TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act
Consolidated Appropriations Act, 2021
Client: PECK MADIGAN JONES (ON BEHALF OF ASSOCIATION FOR CLINICAL ONCOLOGY) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act
Consolidated Appropriations Act, 2021
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 133 / PL 116-260 - FY2021 Omnibus and COVID Relief and Response Act
Families First Coronavirus Response Act
Client: TIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to the Prescription Drug Pricing Reduction Act; HR 6201 Families First Coronavirus Response Act (PL 116-27) - drug pricing issues; CARES Act - S. 3548 (PL 116-136) - drug pricing issues.
Families First Coronavirus Response Act
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to the Prescription Drug Pricing Reduction Act; HR 6201 Families First Coronavirus Response Act (PL 116-27) - drug pricing issues; CARES Act - S. 3548 (PL 116-136) - drug pricing issues.
Families First Coronavirus Response Act
Client: TIBER CREEK GROUP (ON BEHALF OF BRISTOL MYERS SQUIBB) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
HR 6201 Families First Coronavirus Response Act (PL 116-27) - drug pricing issues. CARES Act - S. 3548 (PL 116-136) - drug pricing issues
Families First Coronavirus Response Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to the Prescription Drug Pricing Reduction Act. HR 6201 Families First Coronavirus Response Act (PL 116-27) - drug pricing issues; CARES Act - S. 3548 (PL 116-136) - drug pricing issues; Issues related to pharmaceutical copayments within the CMS Proposed Notice of Benefit and Payment Parameters Rule for 2021
Families First Coronavirus Response Act
Client: GENENTECH, INC. · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to the Prescription Drug Pricing Reduction Act; HR 6201 Families First Coronavirus Response Act (PL 116-27) - drug pricing issues; CARES Act - S. 3548 (PL 116-136) - drug pricing issues; Part B home infusion issues.
Families First Coronavirus Response Act
Client: AMGEN, INC. · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to the Prescription Drug Pricing Reduction Act. HR 6201 Families First Coronavirus Response Act (PL 116-27) - drug pricing issues; CARES Act - S. 3548 (PL 116-136) - drug pricing issues; Part B home infusion issues
Families First Coronavirus Response Act
Client: TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to the Prescription Drug Pricing Reduction Act; HR 6201 Families First Coronavirus Response Act (PL 116-27) - drug pricing issues; CARES Act - S. 3548 (PL 116-136) - drug pricing issues.
Families First Coronavirus Response Act
Client: TIBER CREEK GROUP (ON BEHALF OF EMD SERONO, INC.) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to the Prescription Drug Pricing Reduction Act; HR 6201 Families First Coronavirus Response Act (PL 116-27) - drug pricing issues; CARES Act - S. 3548 (PL 116-136) - drug pricing issues.
Families First Coronavirus Response Act
Client: ELI LILLY AND COMPANY · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
HR 6201 Families First Coronavirus Response Act (PL 116-27) - drug pricing issues; CARES Act - S. 3548 (PL 116-136) - drug pricing issues
CARES Act - S. 3548 (PL 116-136) - drug pricing issues; H.R. 6800 the Health and Economic Recovery Omnibus Emergency Solutions Act
The Heroes Act
Client: TIBER CREEK GROUP (ON BEHALF OF BRISTOL MYERS SQUIBB) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
CARES Act - S. 3548 (PL 116-136) - drug pricing issues. H.R. 6800 the Health and Economic Recovery Omnibus Emergency Solutions Act
CARES Act - S. 3548 (PL 116-136) - drug pricing issues; Part B home infusion issues; H.R. 6800 - Health and Economic Recovery Omnibus Emergency Solutions Act or the Heroes Act
CARES Act - S. 3548 (PL 116-136) - drug pricing issues; H.R. 6800 the Health and Economic Recovery Omnibus Emergency Solutions Act
The Heroes Act
Client: TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
CARES Act - S. 3548 (PL 116-136) - drug pricing issues. H.R. 6800 the Health and Economic Recovery Omnibus Emergency Solutions Act
The Heroes Act
Client: PECK MADIGAN JONES (ON BEHALF OF LEGACY COMMUNITY HEALTH SERVICES) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 6800 the Health and Economic Recovery Omnibus Emergency Solutions Act
The Heroes Act
Client: TIBER CREEK GROUP (ON BEHALF OF EMD SERONO, INC.) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
CARES Act - S. 3548 (PL 116-136) - drug pricing issues. H.R. 6800 the Health and Economic Recovery Omnibus Emergency Solutions Act
CARES Act - S. 3548 (PL 116-136) - drug pricing issues. H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act
The Heroes Act
Client: TIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
CARES Act - S. 3548 (PL 116-136) - drug pricing issues. H.R. 6800 the Health and Economic Recovery Omnibus Emergency Solutions Act
The Heroes Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
H.R. 6800 the Health and Economic Recovery Omnibus Emergency Solutions Act
CARES Act - S. 3548 (PL 116-136) - drug pricing issues. H.R. 6800 the Health and Economic Recovery Omnibus Emergency Solutions Act
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to Part B and Part D pricing; S. 3353 Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020
Comprehensive Immunosuppressive Drug Coverage for Kidney Transplant Patients Act of 2020
Client: NOVARTIS · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to drug pricing; Issues relating to the 340b program; S. 3353 Comprehensive Immunosuppressive drug coverage for Kidney Transplant Patients Act of 2020
CARES Act - S. 3548 (PL 116-136) - drug pricing issues; Part B home infusion issues; H.R. 6800 - Health and Economic Recovery Omnibus Emergency Solutions Act or the Heroes Act
CARES Act
Client: TIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
CARES Act - S. 3548 (PL 116-136) - drug pricing issues. H.R. 6800 the Health and Economic Recovery Omnibus Emergency Solutions Act
CARES Act
Client: PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
Issues related to the Prescription Drug Pricing Reduction Act. HR 6201 Families First Coronavirus Response Act (PL 116-27) - drug pricing issues; CARES Act - S. 3548 (PL 116-136) - drug pricing issues; Issues related to pharmaceutical copayments within the CMS Proposed Notice of Benefit and Payment Parameters Rule for 2021
CARES Act
Client: TIBER CREEK GROUP (ON BEHALF OF BRISTOL MYERS SQUIBB) · Firm: TIBER CREEK HEALTH STRATEGIES, INC.
CARES Act - S. 3548 (PL 116-136) - drug pricing issues. H.R. 6800 the Health and Economic Recovery Omnibus Emergency Solutions Act
CARES Act - S. 3548 (PL 116-136) - drug pricing issues. H.R. 6800, the Health and Economic Recovery Omnibus Emergency Solutions Act
Issues related to the Prescription Drug Pricing Reduction Act; HR 6201 Families First Coronavirus Response Act (PL 116-27) - drug pricing issues; CARES Act - S. 3548 (PL 116-136) - drug pricing issues.
Issues related to Orphan drug coverage under Medicare.
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) via TIBER CREEK HEALTH STRATEGIES, INC.
2025 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) via TIBER CREEK HEALTH STRATEGIES, INC.
2025 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
NOVARTIS via TIBER CREEK HEALTH STRATEGIES, INC.
2025 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R. 5547/S. 476 - Maintaining Investments in New Innovation Act (118th Congress).
Issues related to PBM reform.
Filing targets: SENATE
GRAIL, LLC via TIBER CREEK HEALTH STRATEGIES, INC.
2025 · first_quarter · Q1
Issues related to multi-cancer early detection screening; H.R. 2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act (118th Congress).
Filing targets: HOUSE OF REPRESENTATIVES
GENENTECH, INC. via TIBER CREEK HEALTH STRATEGIES, INC.
2025 · first_quarter · Q1
Issues related to the 340b program - Public Health Service Act (P.L. 78-410); Issues related to PBM reform.
Filing targets: SENATE
FRESENIUS MEDICAL CARE NORTH AMERICA via TIBER CREEK HEALTH STRATEGIES, INC.
2025 · first_quarter · Q1
Issues related to Medicare reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via TIBER CREEK HEALTH STRATEGIES, INC.
2025 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
AMGEN, INC. via TIBER CREEK HEALTH STRATEGIES, INC.
2025 · first_quarter · Q1
Issue related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS) via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF EMD SERONO, INC.) via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · fourth_quarter · Q4
Issues related to IVF policy in National Defense Authorization Act for Fiscal Year 2024 (PL 118-31).
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF BRISTOL MYERS SQUIBB) via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (OBO JAZZ PHARMACEUTICALS) via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · fourth_quarter · Q4
Issues related to Orphan drug coverage under Medicare.
Filing targets: SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
NOVARTIS via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · fourth_quarter · Q4
Issues related to PBM reform.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R.5547/S. 476 - Maintaining Investments in New Innovation Act.
Filing targets: SENATE
GRAIL, LLC via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · fourth_quarter · Q4
Issues related to multi-cancer early detection screening; H.R. 2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Filing targets: HOUSE OF REPRESENTATIVES
GENENTECH, INC. via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · fourth_quarter · Q4
Issues related to the 340b program - Public Health Service Act (PL 78-410); Issues related to PBM reform.
Filing targets: SENATE
FRESENIUS MEDICAL CARE NORTH AMERICA via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · fourth_quarter · Q4
Issues related to Medicare reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Issues related to pharmacy benefit managers reform.
Filing targets: SENATE
AMGEN, INC. via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · fourth_quarter · Q4
Issue related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS) via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (OBO JAZZ PHARMACEUTICALS) via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · third_quarter · Q3
Issues related to orphan drug coverage under Medicare.
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF BRISTOL MYERS SQUIBB) via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
NOVARTIS via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · third_quarter · Q3
Issues related to PBM reform.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R.5547/S. 476 - Maintaining Investments in New Innovation Act.
Filing targets: SENATE
GRAIL, LLC via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · third_quarter · Q3
Issues related to multi-cancer early detection screening; H.R. 2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Filing targets: HOUSE OF REPRESENTATIVES
GENENTECH, INC. via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · third_quarter · Q3
Issues related to the 340b program - Public Health Service Act (PL 78-410); Issues related to PBM reform.
Filing targets: SENATE
FRESENIUS MEDICAL CARE NORTH AMERICA via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · third_quarter · Q3
Issues related to Medicare reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Issues related to pharmacy benefit managers.
Filing targets: SENATE
AMGEN, INC. via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · third_quarter · Q3
Issue related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS) via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (OBO JAZZ PHARMACEUTICALS) via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF BRISTOL MYERS SQUIBB) via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
NOVARTIS via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R.5547/S. 476 - Maintaining Investments in New Innovation Act.
Filing targets: SENATE
GRAIL, LLC via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · second_quarter · Q2
Issues related to multi-cancer early detection screening; H.R. 2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Filing targets: HOUSE OF REPRESENTATIVES
GENENTECH, INC. via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · second_quarter · Q2
Issues related to the 340b program - Public Health Service Act (PL 78-410).
Filing targets: SENATE
FRESENIUS MEDICAL CARE NORTH AMERICA via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · second_quarter · Q2
Issues related to Medicare reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Issues related to pharmacy benefit managers.
Filing targets: SENATE
AMGEN, INC. via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · second_quarter · Q2
Issue related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS) via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (OBO JAZZ PHARMACEUTICALS) via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF BRISTOL MYERS SQUIBB) via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Issues related to the 340b program.
Filing targets: SENATE
NOVARTIS via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340B Drug Pricing Program; Issues related to drug pricing; Issues related to pharmacy benefit managers.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); H.R.5547/S. 476 - Maintaining Investments in New Innovation Act.
Filing targets: SENATE
GRAIL, LLC via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · first_quarter · Q1
Issues related to multi-cancer early detection screening; H.R. 2407 - Nancy Gardner Sewell Medicare Multi-Cancer Early Detection Screening Coverage Act.
Filing targets: HOUSE OF REPRESENTATIVES
GENENTECH, INC. via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Issues related to the 340b program - Public Health Service Act (PL 78-410).
Filing targets: SENATE
FRESENIUS MEDICAL CARE NORTH AMERICA via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · first_quarter · Q1
Issues related to Medicare reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Issues related to pharmacy benefit managers.
Filing targets: SENATE
AMGEN, INC. via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · first_quarter · Q1
Issue related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
GRAIL, LLC via TIBER CREEK HEALTH STRATEGIES, INC.
2024 · first_quarter · RR
Issues related to Medicare and cancer screening.
TIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Issues related to sickle cell treatment.
Filing targets: Health & Human Services, Dept of (HHS), SENATE
TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF EMD SERONO, INC.) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF BRISTOL MYERS SQUIBB) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Issues related to the HHS Notice of Benefit and Payment Parameters.
Filing targets: SENATE
TIBER CREEK GROUP (OBO JAZZ PHARMACEUTICALS) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Issues related to FDA oversight of CBD.
Filing targets: SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · fourth_quarter · Q4
Issues related to the 340b program.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
NOVARTIS via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340B Drug Pricing Program; General intellectual property issues; Issues related to drug pricing; Issues related to pharmacy benefit managers.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); S. 476 - Maintaining Investments in New Innovation Act.
Filing targets: SENATE
GENENTECH, INC. via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Issues related to the HHS Notice of Benefit and Payment Parameters.
Filing targets: SENATE
FRESENIUS MEDICAL CARE NORTH AMERICA via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · fourth_quarter · Q4
Issues related to Medicare reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · fourth_quarter · Q4
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
AMGEN, INC. via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · fourth_quarter · Q4
Issue related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022. (PL 117-169).
Filing targets: SENATE
NOVARTIS via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · third_quarter · 3A
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); Issues related to the 340B Drug Pricing Program; General intellectual property issues; Issues related to drug pricing; Issues related to pharmacy benefit managers.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); S. 476 - Maintaining Investments in New Innovation Act.
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF BRISTOL MYERS SQUIBB) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Issues related to the 340b program.
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF EMD SERONO, INC.) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (OBO JAZZ PHARMACEUTICALS) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · third_quarter · Q3
Issues related to FDA oversight of CBD.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Issues related to the 340b program.
Filing targets: SENATE
NOVARTIS via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); S. 476 - Maintaining Investments in New Innovation Act.
Issues related to pharmacy benefit managers.
Filing targets: SENATE
ELI LILLY AND COMPANY via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · third_quarter · Q3
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
GENENTECH, INC. via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · third_quarter · Q3
Issues related to the 340b program.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
FRESENIUS MEDICAL CARE NORTH AMERICA via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · third_quarter · Q3
Issues related to Medicare reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
AMGEN, INC. via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · third_quarter · Q3
Issue related to implementation of drug pricing and reimbursement for prescription drugs in the Inflation Reduction Act of 2022. (PL 117-169).
Filing targets: SENATE
NOVARTIS via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · second_quarter · 2A
Issues related to pharmacy benefit managers.
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); S. 476 - Maintaining Investments in New Innovation Act.
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (OBO JAZZ PHARMACEUTICALS) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Issues related to FDA oversight of CBD.
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF EMD SERONO, INC.) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF BRISTOL MYERS SQUIBB) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
NOVARTIS via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); S. 476 - Maintaining Investments in New Innovation Act.
Filing targets: SENATE
GENENTECH, INC. via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
FRESENIUS MEDICAL CARE NORTH AMERICA via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · second_quarter · Q2
Issues related to Medicare reimbursement.
Filing targets: HOUSE OF REPRESENTATIVES, SENATE
ELI LILLY AND COMPANY via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
AMGEN, INC. via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · second_quarter · Q2
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF VERTEX PHARMACEUTICALS) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF EMD SERONO, INC.) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF MERCK & CO INC) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
TIBER CREEK GROUP (OBO JAZZ PHARMACEUTICALS) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Issues related to FDA oversight of CBD.
Filing targets: SENATE
TIBER CREEK GROUP (ON BEHALF OF BRISTOL MYERS SQUIBB) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
PHARMACEUTICAL RESEARCH AND MANUFACTURERS OF AMERICA (PHRMA) via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
NOVARTIS via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169); S. 476 - Maintaining Investments in New Innovation Act.
Filing targets: SENATE
GENENTECH, INC. via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · first_quarter · Q1
Issues related to implementation of drug pricing and reimbursement for prescription drugs in Inflation Reduction Act of 2022 (PL 117-169).
Filing targets: SENATE
FRESENIUS MEDICAL CARE NORTH AMERICA via TIBER CREEK HEALTH STRATEGIES, INC.
2023 · first_quarter · Q1
Issues related to Medicare reimbursement.
Medicare reimbursement issues within Consolidated Appropriations Act, 2023 (PL 117-328).
Filing targets: HOUSE OF REPRESENTATIVES, SENATE